Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Oct-Dec;4(4):163-73.
doi: 10.4103/2278-330X.175953.

Recurrent Glioblastoma: Where we stand

Sanjoy Roy  1 , Debarshi Lahiri  1 , Tapas Maji  1 , Jaydip Biswas  1
Affiliations
Review

Recurrent Glioblastoma: Where we stand

Sanjoy Roy et al. South Asian J Cancer. 2015 Oct-Dec.

Retraction in

Abstract

Current first-line treatment regimens combine surgical resection and chemoradiation for Glioblastoma that provides a slight increase in overall survival. Age on its own should not be used as an exclusion criterion of glioblastoma multiforme (GBM) treatment, but performance should be factored heavily into the decision-making process for treatment planning. Despite aggressive initial treatment, most patients develop recurrent diseases which can be treated with re-resection, systemic treatment with targeted agents or cytotoxic chemotherapy, reirradiation, or radiosurgery. Research into novel therapies is investigating alternative temozolomide regimens, convection-enhanced delivery, immunotherapy, gene therapy, antiangiogenic agents, poly ADP ribose polymerase inhibitors, or cancer stem cell signaling pathways. Given the aggressive and resilient nature of GBM, continued efforts to better understand GBM pathophysiology are required to discover novel targets for future therapy.

Keywords: Chemotherapy; glioblastoma multiforme; glioma; targeted therapy; temozolomide.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

References

    1. Apuzzo ML. Park Ridge, IL: American Association of Neurological Surgeons; 1990. Malignant Cerebral Glioma (Neurosurgical Topics, 2)
    1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96. - PubMed
    1. Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: An analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J Neurosurg. 1998;88:1–10. - PubMed
    1. McLendon RE, Halperin EC. Is the long-term survival of patients with intracranial glioblastoma multiforme overstated? Cancer. 2003;98:1745–8. - PubMed
    1. Salvati M, Cervoni L, Artico M, Caruso R, Gagliardi FM. Long-term survival in patients with supratentorial glioblastoma. J Neurooncol. 1998;36:61–4. - PubMed